Human glioblastoma multiforme (GBM) is the most malignant form of human brain tumors. A characteristic of GBM is the marked presence of tumor infiltrated microglia/macrophages and lymphocytes. The goal of this study was directed toward understanding the role of the chemokine system CX3CL1 and its receptor CX3CR1 in the GL261 murine model of malignant glioma. In situ hybridization analysis identified CX3CL1 and CX3CR1 expression in GL261 tumors. The impact of CX3CR1 deletion on the growth of intracranial GL261 gliomas and associated immune cell infiltration was evaluated in CX3CR1 gene-disrupted C57BL/6 mice. A slight increase in the tumor growth rate in CX3CR1−/− mice was evident with similar numbers of microglia and CD4 + , CD8 + , FoxP3 + , or Ly49G2 + lymphocytes within tumors established in CX3CR1 +/− and −/− mice. These data indicate that CX3CR1 has little or no effects on either gliomagenesis or the migration of microglia and lymphocytes into GL261 tumors.
Introduction
Human glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and malignant form of human primary brain tumors. GBM patients have a less than 2% 5 year survival rate. Current standard treatment of GBM is surgical resection of the tumor mass, followed by adjuvant radiotherapy and chemotherapy. However, these treatments are not very successful and have only a modest impact on the survival rate of GBM patients. Due to the relative ineffectiveness of these traditional treatments, other methods, such as immunotherapy, are being evaluated (Kawakami et al., 2008) .
The marked presence of glioma infiltrating microglia and lymphocytes supports the concept of targeting the immune system to treat GBM. Studies indicate that murine microglia express multiple Toll like receptors (Olson and Miller, 2004) and are able to activate CD4 + helper T cells (McMahon et al., 2005) . However, successful immunotherapy of GBM will involve overcoming the highly immunosuppressive environment created by the tumor, that includes immunosuppressive cytokines such as TGFβ and Interleukin 10 (Roussel et al., 1996) and immune cells such as the regulatory T cell (Fecci et al., 2006) . A greater understanding of the immune response during glioma formation will help in the development of improved therapeutics.
Chemokines are small proteins that induce chemotaxis of responsive cells and are attractive molecules to mediate the migration of immune cells into the tumor. In addition to these chemoattractive functions, chemokines also exert direct effects on tumor growth, angiogenesis, and metastasis. For example, inhibition of CXCR4/CXCL12 signaling pathway decreased
